14 completed, 12 terminated, 2 no longer available, 1 unknown. 10 Phase 2, 9 Phase 1, 5 Phase 3, 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Terminated 6, Completed 3, Unknown 1 |
| Phase 1 | 9 | Completed 7, Terminated 2 |
| Phase 3 | 5 | Terminated 4, Completed 1 |
| Phase 4 | 3 | Completed 2, Withdrawn 1 |
Follow voxelotor: new trials by email Literature Review of voxelotor trials Research Report on voxelotor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing Physical Function in Sickle Cell Patients Taking Voxelotor Voxelotor - Sickle Cell Disease | Phase 2 | Completed | Inova Health Care Services | 6 | 2023-10-23 | 2026-08-31 |
| Voxelotor Brain Oxygenation and Neurocognitive Study Voxelotor Oral Tablet - Sickle Cell Disease | Phase 4 | Withdrawn | Pfizer | 2023-08-09 | 2024-08-09 | |
| Voxelotor CYP and Transporter Cocktail Interaction Study Voxelotor, Bupropion, Repaglinide - Sickle Cell Disease | Phase 1 | Completed | Pfizer | 44 | 2023-04-17 | 2024-11-22 |
| Hemolysis Related Complications in SCD. A Phase II Study With Voxelotor Voxelotor 1500 mg oral per day (GBT440) for 48 weeks in patients with sickle-cell disease - Sickle Cell Disease | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 30 | 2023-03-22 | 2023-09-21 |
| Resolution of Sickle Cell Leg Ulcers With Voxelotor Voxelotor Oral Tablet, Placebo - Sickle Cell Disease, Leg Ulcers | Phase 3 | Terminated | Pfizer | 88 | 2022-05-30 | 2025-07-09 |
| Voxelotor for Improving Oxygen Saturation in Adults Voxelotor - Acute Lung Injury, End Stage Lung Disease | Phase 2 | Terminated | Duke University | 3 | 2022-05-03 | 2024-07-24 |
| The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia Voxelotor - Sickle Cell Anemia in Children | Phase 2 | Terminated | Emory University | 22 | 2022-03-28 | 2025-12-12 |
| Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD Oxbryta® (voxelotor) 500mg Tablets - Sickle Cell Disease | Terminated | Pfizer | 265 | 2022-02-04 | 2025-12-31 | |
| Retrospective Real World Oxbryta® Data Collection and Analysis Study Oxbryta® (voxelotor) 500-mg Tablets - Sickle Cell Disease | Completed | Pfizer | 216 | 2021-03-20 | 2024-03-06 | |
| A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease Voxelotor - Sickle Cell Disease, Sickle Cell Nephropathy | Phase 1 / Phase 2 | Terminated | University of Illinois at Chicago | 12 | 2021-03-16 | 2025-04-03 |
| Actigraphy Improvement With Voxelotor (ActIVe) Study Voxelotor - Sickle Cell Disease, Sickle Cell Anemia | Phase 4 | Completed | Pfizer | 25 | 2020-12-21 | 2023-11-21 |
| Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease Voxelotor, Placebo - Sickle Cell Disease | Phase 3 | Terminated | Pfizer | 236 | 2020-11-11 | 2026-03-10 |
| Voxelotor Sickle Cell Exercise Study Voxelotor - Sickle Cell Anemia | Phase 4 | Completed | Elizabeth Yang, MD, PhD | 14 | 2020-09-21 | 2022-06-15 |
| Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCD Voxelotor - Sickle Cell Disease | Phase 2 | Terminated | Pfizer | 6 | 2020-01-09 | 2023-11-21 |
| Open-Label Extension of Voxelotor Voxelotor - Sickle Cell Disease | Phase 3 | Terminated | Pfizer | 162 | 2019-11-18 | 2025-11-13 |
| Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031 Voxelotor - Sickle Cell Disease | Phase 3 | Terminated | Pfizer | 179 | 2018-06-06 | 2025-11-18 |
| Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment GBT440 - Hepatic Impairment | Phase 1 | Completed | Pfizer | 29 | 2017-03-17 | 2023-07-18 |
| Study to Evaluate Effects of Investigational Drug on Oxygenation in Healthy Volunteers Under Hypoxic Conditions GBT440 - Cardio-pulmonary Function | Phase 1 | Terminated | Global Blood Therapeutics | 14 | 2016-12-01 | 2019-10-04 |
| Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE) voxelotor, Placebo - Sickle Cell Disease | Phase 3 | Completed | Pfizer | 449 | 2016-12-01 | 2023-07-27 |
| Single-Dose PK Study of GBT440 in Subjects With Renal Impairment GBT440 - Renal Impairment | Phase 1 | Completed | Global Blood Therapeutics | 16 | 2016-11-01 | 2018-02-22 |
Showing 20 of 30. Sign in to see all of them.
Anemia, Sickle Cell (23) · Hypoxia (2) · Idiopathic Pulmonary Fibrosis (2) · Acute Lung Injury (1) · Hemolysis (1) · Leg Ulcer (1) · Renal Insufficiency (1)
Pfizer (15) · Global Blood Therapeutics (9) · Assistance Publique - Hôpitaux de Paris (1) · Duke University (1) · Elizabeth Yang, MD, PhD (1) · Emory University (1) · Inova Health Care Services (1) · University of Illinois at Chicago (1)
United States (25) · United Kingdom (9) · Egypt (4) · Kenya (4) · Lebanon (4) · France (3) · Italy (3) · Nigeria (3) · Oman (3) · Brazil (2) · Canada (2) · Netherlands (2) · Turkey (Türkiye) (2) · Ghana (1) · Jamaica (1)
Carla Washington, PhD (3) · Josh Lehrer-Graiwer, MD (2) · Amy Tang, MD (1) · Carla Washington (1) · Elizabeth Yang, MD, PhD. (1) · Ganesh Balaratnam, MBChB, BAO (1) · Ian Welsby (1) · Kari Wheeler, BSN, RN (1) · Pierre-Andre Natella, PHD (1) · Sheinei Alan (1) · Timothy Mant, FRCP FFPM (1) · Timothy Mant, FRCP, FFPM (1) · Vivian Phan, MS (1)
PMID 30655275, PMID 41701977, PMID 28337324, PMID 31199090, PMID 33476432, PMID 33838113, PMID 35451176, PMID 37247190, PMID 37254256, PMID 38364110, PMID 41603130, PMID 42665434
2014 (1), 2017 (1), 2019 (1)